NJ State Employees Deferred Compensation Plan’s Cytokinetics CYTK Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,500	Closed	-$852K	–	110
2025 Q3	$852K	Hold	15,500	–	–	0.09%	205
2025 Q2	$512K	Hold	15,500	–	–	0.06%	277
2025 Q1	$623K	Hold	15,500	–	–	0.08%	232
2024 Q4	$729K	Hold	15,500	–	–	0.09%	220
2024 Q3	$818K	Hold	15,500	–	–	0.1%	205
2024 Q2	$840K	Hold	15,500	–	–	0.1%	190
2024 Q1	$1.09M	Hold	15,500	–	–	0.14%	163
2023 Q4	$1.29M	Hold	15,500	–	–	0.18%	124
2023 Q3	$457K	Hold	15,500	–	–	0.07%	277
2023 Q2	$506K	Hold	15,500	–	–	0.07%	271
2023 Q1	$545K	Buy	15,500 +8,000	+107%	+$326K	0.08%	253
2022 Q4	$344K	Hold	7,500	–	–	0.06%	342
2022 Q3	$363K	Buy	+7,500	New	+$361K	0.06%	320

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's CYTK Position: Q4 2025 in Review

NJ State Employees Deferred Compensation Plan sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 15,500 shares — an estimated $852K sold.

NJ State Employees Deferred Compensation Plan first reported a position in CYTK in Q3 2022 and held it in 13 quarters. The position peaked at $1.29M in Q4 2023. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

NJ State Employees Deferred Compensation Plan reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 15,500 Cytokinetics shares in Q4 2025, an estimated $852K.
NJ State Employees Deferred Compensation Plan first reported a position in Cytokinetics in Q3 2022 and held it in 13 quarters.
NJ State Employees Deferred Compensation Plan's Cytokinetics position peaked at $1.29M in Q4 2023.
430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q4 2025.